KBC Securities - Deceuninck S.A. (DECB) Morning Note: DECB BB

Report

KBC Securities

Wim Hoste

Morning Note: DECB BB

Deceuninck: 1H adj EBITDA drops (only) 8%

18/08/2020 5 EN

Underlying

Deceuninck S.A.

Deceuninck is an international designer and manufacturer of PVC systems for windows and doors, cladding & roofline, interior and garden applications. The basic technology used by Co. is extrusion of PVC and patented Twinson composite material. The production process includes compounding, tool manufacturing, extrusion of gaskets and profiles, printing, PVC lamination and the patented Decoroc coating technology. Co. is active in more than 75 countries across Europe, North America and Asia and maintains nine PVC extrusion facilities capable of processing 260,000 tons of compound.

See profile

BE0003789063 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Wim Hoste

Other Reports on these Companies

KBC Securities

Local Champions Mid Cap Conference Book 11.12.2025

December 3, 2025 December 3, 2025 1 EN

SmartInsider

Deceuninck NV: 2 directors

Two Directors at Deceuninck NV bought 8,550 shares at between 2.030EUR and 2.050EUR. The significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. ...

Free Trial

November 18, 2025 November 18, 2025 1 EN

ING Financial Markets

Deceuninck/1H25: weak performance in Turkey/HOLD

We reiterate our HOLD on Deceuninck, but lower our target price to €2.3, from €2.5, following the group's 1H25 results. We note that the profitability in Turkey has disappointed, following a double-digit drop in sales, materially below the Street's expectations. Turkey accounted for >50% of group Adj. EBITDA last year. We expect high interest rates and inflation to continue to negatively affect the group's operating profit, but also its financial expenses due to its hedging policy in the country. At our target price of €2.3, Deceuninck would trade at a Normalised PER of 8.6x in 2026F, in line ...

August 25, 2025 August 25, 2025 1 EN

Barco Despite US headwinds more or less in line but order cycles shortening

FY2025 was more or less in line with our and CSS forecasts, demonstrating resilience amid global challenges and “setting up a foundation for future growth”. We maintain our prudence stance as -while FY2025 shows that Barco can return to sales and margin growth under difficult conditions- the year also exposed clear vulnerabilities—most notably in order intake, which fell 5% YoY (–2% at constant FX) and declined across several divisions and regions. The contraction in orders, combined with the steep drop in the orderbook (€492.8m vs. €563.7m), highlights a weakening forward demand environment t...

13m 13m 1 EN

Michiel Declercq

Michiel Declercq

Philips Strong 4Q25 results and outlook, targets mid-teens margins by 2028

Philips reported a strong set of 4Q25 results with the adj. EBITA of € 770m coming in well ahead of expectations (kbcse: € 678m, css: € 672m), predominantly driven by PH. Order intake remained strong at +7%. The FY26 margin outlook of 12.5%-13.0% also came in ahead of expectations (kbcse: 12.3%, css: 12.2%). Together with the CMD that will take place in London today, the group also announced its new 2026-2028 ambitions, including a mid-teens margins by 2028 (kbcse: 13.5%, css 13.6%) and accumulative FCF between € 4.5- € 5.0bn (kbcse: € 4.4bn, css: € 4.0bn). We reiterate our Accumulate rating a...

19m 19m 1 EN

Guy Sips

Guy Sips

Biotalys Model update after strategic refocus

We updated our model (New “Accumulate”, New € 5.1 TP) after Biotalys plans a strategic refocus, concentrating resources on its top-priority biofungicide programs. Early-stage activities will be suspended and the organization downsized to cut costs while they claim “protecting long-term platform value”. The shift prioritizes Evoca NG, BioFun-6, and already partnered programs with the Gates Foundation and Syngenta. These measures aim to reduce cash burn by €20m through 2028 and strengthen commercialization readiness. Biotalys intends to cut 30 jobs (In 2025 Biotalys on average had 59 employees.)...

42m 42m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Morning Note: DECB BB

We are a financial services provider for several types of professional clients, each with distinct needs.

Local Champions Mid Cap Conference Book 11.12.2025

Deceuninck NV: 2 directors

Deceuninck/1H25: weak performance in Turkey/HOLD

Barco Despite US headwinds more or less in line but order cycles shortening

Philips Strong 4Q25 results and outlook, targets mid-teens margins by 2028

Biotalys Model update after strategic refocus

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe